Psilocybin for anhedonia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 30 Jan 2024: Trial registered, NCT06230757
  2. 8 Jul 2024: Trial started, NCT06230757

The trials

NCT05601648: PET Synaptogenesis After Psilocybin In DEpression Recovery

State
Withdrawn before it started
Phase
Phase 2
People
0 taking part
Started
1 Jul 2023
Primary completion
1 Jan 2025
Arms
Psilocybin
Results
None posted
  1. 1 Nov 2022: Trial registered
  2. 30 Jan 2023: Trial withdrawn

NCT06230757: Psilocybin for Treatment-Resistant Depression

State
Completed
Phase
Phase 2
People
20 taking part
Started
8 Jul 2024
Primary completion
8 May 2026
Arms
Psilocybin
Results
None posted
  1. 30 Jan 2024: Trial registered
  2. 8 Jul 2024: Trial started
  3. 8 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.